Derivatives of 9-phosphorylated acridine as butyrylcholinesterase inhibitors with antioxidant activity and the ability to inhibit β-amyloid self-aggregation: potential therapeutic agents for Alzheimer’s disease

We investigated the inhibitory activities of novel 9-phosphoryl-9,10-dihydroacridines and 9-phosphorylacridines against acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and carboxylesterase (CES). We also studied the abilities of the new compounds to interfere with the self-aggregation of β-amyloid (Aβ42) in the thioflavin test as well as their antioxidant activities in the ABTS and FRAP assays. We used molecular docking, molecular dynamics simulations, and quantum-chemical calculations to explain experimental results. All new compounds weakly inhibited AChE and off-target CES. Dihydroacridines with aryl substituents in the phosphoryl moiety inhibited BChE; the most active were the dibenzyloxy derivative 1d and its diphenethyl bioisostere 1e (IC50 = 2.90 ± 0.23 µM and 3.22 ± 0.25 µM, respectively). Only one acridine, 2d, an analog of dihydroacridine, 1d, was an effective BChE inhibitor (IC50 = 6.90 ± 0.55 μM), consistent with docking results. Dihydroacridines inhibited Aβ42 self-aggregation; 1d and 1e were the most active (58.9% ± 4.7% and 46.9% ± 4.2%, respectively). All dihydroacridines 1 demonstrated high ABTS•+-scavenging and iron-reducing activities comparable to Trolox, but acridines 2 were almost inactive. Observed features were well explained by quantum-chemical calculations. ADMET parameters calculated for all compounds predicted favorable intestinal absorption, good blood–brain barrier permeability, and low cardiac toxicity. Overall, the best results were obtained for two dihydroacridine derivatives 1d and 1e with dibenzyloxy and diphenethyl substituents in the phosphoryl moiety. These compounds displayed high inhibition of BChE activity and Aβ42 self-aggregation, high antioxidant activity, and favorable predicted ADMET profiles. Therefore, we consider 1d and 1e as lead compounds for further in-depth studies as potential anti-AD preparations.


Introduction
This paper represents a continuation of our ongoing program of drug discovery for neurodegenerative conditions, with a particular emphasis on Alzheimer's disease (AD).We have focused on AD for several reasons.For example, among the various types of age-related dementias, AD is the most prevalent.Moreover, AD is devastating for patients and their caregivers.It begins with memory loss, progresses to steady declines in cognitive function, and ultimately results in total disability and death (Calabro et al., 2021).Furthermore, there is no cure; treatment has been limited to partial alleviation of symptoms using the few drugs thus far approved by the FDA (Huang and Mucke, 2012;Cummings et al., 2019).
A major impediment to progress in drug discovery for AD is that the disease does not have a single cause; rather, it is multifactorial (Carreiras et al., 2013;Bachurin et al., 2017).Accordingly, our approach is to combine into single molecules the capabilities to inhibit several of the biological macromolecules or processes involved in the pathogenesis of the disease (Makhaeva et al., 2019c;Bachurin et al., 2023).In the present investigation, we have included the following targets: cholinergic neurotransmission, oxidative stress, and Aβ aggregation, as discussed in turn below.
One of the hallmarks of AD pathology is the demise of cholinergic neurons (Ballard et al., 2005;Hampel et al., 2019).Consequently, during the clinical course of the disease, the activity of acetylcholinesterase (AChE) decreases.In an apparent attempt to compensate for the loss of AChE activity, the activity of butyrylcholinesterase (BChE) increases (Ballard et al., 2005).Nevertheless, in the AD brain, there is an overall deficit of the neurotransmitter, acetylcholine (ACh).Therefore, inhibitors of one or both cholinesterases have been used to increase ACh concentrations in an effort to offset cognitive decline due to impaired cholinergic neurotransmission (Lane et al., 2006;Macdonald et al., 2014).Unfortunately, inhibition of cholinesterase activity on its own is insufficient to halt or retard the underlying neuropathic processes (Martinez and Castro, 2006;Agatonovic-Kustrin et al., 2018).
Among the mechanisms thought to contribute to AD pathogenesis is oxidative stress, which can lead to neuronal death by damaging the lipid and protein constituents of mitochondria, other organelles, and plasma membranes.This situation arises when the concentrations of reactive oxygen species (ROS) in susceptible sites reach critical levels due to their rates of production exceeding their rates of removal (Ortiz et al., 2017;Pohanka, 2018).Although antioxidant processes in the brain decrease with increasing age, these processes are further compromised in AD brain.Consequently, antioxidants are considered to be of adjunctive value in treating AD (Moreira et al., 2005).Indeed, antioxidant properties can be incorporated into drug candidates that contain pharmacophores directed against other targets, such as cholinesterases (Rosini et al., 2011;Ismaili and Romero, 2017;Makhaeva et al., 2020).
Accumulation of Aβ plaques is another process that has been amply linked to AD pathology (Walsh et al., 2005;Castellani et al., 2019;Jeremic et al., 2021).In view of this, under its new accelerated approval program, the FDA has recently approved two monoclonal antibody drugs that could potentially attenuate AD progression by clearing Aβ plaques from the brain (Vaz et al., 2022;van Dyck et al., 2023).However, these approvals have been controversial owing to concerns regarding safety and efficacy (Reardon, 2023).Another approach is to understand the mechanisms of formation of neurotoxic Aβ oligomers and to design compounds to intervene (Jeremic et al., 2021), which was the strategy we employed in our present investigation.
In particular, in our previous work, we studied the esterase profile and estimated the antioxidant activity (AOA) of four groups of new 9-substituted acridine derivatives (Makhaeva et al., 2017).We demonstrated that 9-amino-N-methyl-9,10-dihydroacridine derivatives combined effective inhibition of AChE and BChE with a high level of radical-scavenging activity.
The aim of the present investigation was to study the possibility of creating multifunctional agents for AD therapy based on new 9phosphoryl-9,10-dihydroacridines and 9-phosphorylacridines with various structures of the phosphoryl fragment, obtained using our original strategy of functionalization of acridines by nucleophilic aromatic substitution of hydrogen (S N H ) (Chupakhin et al., 1994;Charushin and Chupakhin, 2004;Chupakhin and Charushin, 2017).We were encouraged to pursue 9-phosphoryl derivatives by the observation that connecting acridine with a phosphorus moiety could enhance penetration of acridines through cell membranes (Demkowicz et al., 2016).In addition, recently studied N-and O-phosphorylated tacrines (Przybylowska et al., 2022) demonstrated high anti-AChE and anti-BChE activities, and some of them had reduced hepatotoxicity compared to tacrine.
In summary, we chose to investigate the effects of our new compounds on the components of AD pathogenesis outlined above: cholinergic neurotransmission, oxidative stress, and Aβ aggregation.Accordingly, we determined the following characteristics of the synthesized compounds: the esterase profile, i.e., the inhibitory activities against AChE, BChE, and a structurally related off-target carboxylesterase (CES, EC 3.1.1.1);inhibition of Aβ self-aggregation; and antioxidant activities in the ABTS and FRAP assays.We then analyzed the observed effects using quantum chemical calculations and computational molecular modeling.Finally, we carried out computational predictions of ADMET properties.

Biological investigations
Experiments were performed in alignment with the standard operating procedures approved by IPAS RAS as described below.

In vitro inhibition of AChE, BChE, and CES activities
Enzymes, substrates, and reference compounds were from Sigma-Aldrich (St. Louis, MO, United States).The activity of enzymes was measured spectrophotometrically, as described in detail in (Makhaeva et al., 2017) using ATCh iodide, BTCh iodide, and 4-NPA as substrates for AChE, BChE, and CES, respectively.Experimental conditions: K,Na-phosphate buffer (100 mM), 25 °S, pH 7.5 for AChE and BChE and pH 8.0 for CES assay.Measurements were carried out on a BioRad Benchmark Plus microplate spectrophotometer (Hercules, CA, United States).
Test compounds were dissolved in DMSO; final concentration of solvent in the incubation mixture was 2% (v/v).Initial assessment of inhibitory activity was carried out by determining the degree of enzyme inhibition at a compound concentration of 20 µM.For the most active compounds (inhibition ≥35%), IC 50 values were determined.
Mechanism of BChE inhibition was assessed by a detailed analysis of enzyme kinetics with three increasing concentrations of inhibitor and six substrate concentrations as described in detail in Makhaeva et al. (2017).

Inhibition of β-amyloid (1-42) (Aβ 42 ) selfaggregation
Inhibition of Aβ 42 self-aggregation by test compounds was studied using the thioflavin T (ThT) fluorescence method (LeVine, 1999;Bartolini et al., 2003;Munoz-Ruiz et al., 2005) with minor modifications as described in detail in (Makhaeva et al., 2023).Lyophilized HFIP-pretreated Aβ 42 (AnaSpec Inc., 0.5 mg) was dissolved in DMSO to obtain a stable 500 μM solution.The samples of 50 μM Aβ 42 in 215 mM Na-phosphate buffer pH 8.0 were incubated for 24 h at 37 °C in the absence or presence of 100 µM test compounds.Myricetin and Propidium iodide in the same concentration were used as references.After incubation, 5 μM ThT in 50 mM glycine-NaOH buffer pH 8.5 was added, and the fluorescence was measured at 440 nm (exc.) and 485 nm (emis.)with a FLUOStar Optima microplate reader (LabTech, Ortenberg, Germany).Blanks consisted of 215 mM Na-phosphate buffer, pH 8.0, 20% (v/v) DMSO or test compounds, respectively.(Re et al., 1999), with minor modifications described in detail in Makhaeva et al. (2019a).To prepare the solution of ABTS •+ , equal volumes of aqueous solutions of 7 mM ABTS and 2.45 mM potassium persulfate were incubated for 12-16 h at room temperature in the dark.Radical scavenging capacity of the compounds was determined by mixing 10 μL of compound solution in DMSO with 240 μL of ABTS •+ working solution in ethanol (100 μM final concentration).The reduction in ABTS •+ absorbance was measured spectrophotometrically at 734 nm using a xMark UV/VIS microplate spectrophotometer (Bio-Rad, Hercules, CA, United States) for 1 h with an interval of 10 min compared to a standard synthetic antioxidant Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid).Ascorbic acid was used as a positive control.
The antioxidant activity of the compounds was reported as Trolox equivalent antioxidant capacity (TEAC values) as the ratio of the slopes of the concentration−response curves, test compound/ Trolox.The IC 50 values for the test compounds were also determined.

FRAP assay
The ferric reducing antioxidant power (FRAP) assay proposed by Benzie and Strain (1996); Benzie and Strain (1999) modified to be performed in 96-well microplates as described in detail in Makhaeva et al. (2020) was used.10 μL (0.5 mM) of the tested or reference compounds were mixed with 240 µL of FRAP reagent (2.5 mL of 10 mM TPTZ (2,4,6-tris(2-pyridyl)-s-triazine) solution in 40 mM HCl, 2.5 mL of 20 mM FeCl 3 in distilled water and 25 mL of 0.3 M acetate buffer pH 3.6); the absorbance of the mixture was measured spectrophotometrically (λ = 593 nm) with a FLUOStar OPTIMA microplate reader at 600 nm after a 1 h incubation at 37 °C against a blank.Trolox was used as a reference compound.The results were expressed as Trolox equivalents (TE)-the ratio of the concentrations of Trolox and the test compound resulting in the same effect on ferric reducing activity.

Statistical analyses
Plots, linear regressions, and IC 50 values were determined using Origin 6.1 for Windows, OriginLab (Northampton, MA, United States).All tests were performed at least in triplicate in three independent experiments.Results are presented as mean ± SEM calculated using GraphPad Prism version 6.05 for Windows (San Diego CA, United States).

Molecular modeling studies 2.4.1 Molecular docking
The Calculator Plugins of MarvinSketch 21.14.0,ChemAxon (https://www.chemaxon.com,accessed on 27 January 2023) and MolGpKa (Pan et al., 2021) (https://xundrug.cn/molgpka,accessed on 27 January 2023) were used to estimate the pK a values of the ligands.Because the pK a values of the acridine fragments for all considered compounds were estimated to be below 5, all conjugates were utilized for molecular docking in their neutral form.The ligand compounds were optimized using a DFT quantum chemistry method (B3LYP/6-31G*, GAMESS-US (Schmidt et al., 1993) software).For molecular docking, the optimized structures of the ligands were employed, with partial atomic charges obtained from QM results based on the Löwdin scheme (Löwdin, 1970).

Molecular dynamics simulations
For molecular dynamics (MD) simulations, an initial complex of BChE with the most active compound 1d was taken from molecular docking results.Crystallographic waters found in the initial protein X-ray structure were added, except for ones overlapping with the inhibitor molecule.TIP3P water molecules were added, forming a box with boundaries extending 10 Å beyond the protein using the VMD solvate module.Na + and Cl − ions were added up to 150 mM ion concentration, and the neutral state of the whole system was achieved using the VMD autoionize module.Force field parameters of the ligand were derived with the CharmGenFF program v. 2.5 (Vanommeslaeghe et al., 2010).
MD simulation was performed with NAMD 3.0b2 software (Phillips et al., 2020) using the CHARMM36 force field (Vanommeslaeghe et al., 2010).During MD simulation, the system was maintained at constant temperature (298 K) and pressure (1 atm, NPT ensemble), using Langevin dynamics and the Nosé-Hoover barostat; the timestep was 1 fs.Periodic boundary conditions and PME electrostatics were applied.Before the productive MD run, a system minimization was conducted during 3,000 steps; next, a 1 ns solvent equilibration run was carried out with the protein and ligand coordinates fixed, and then the structure was fully minimized during 3,000 steps.After that, a 50 ns production run was performed.Analysis of the obtained MD trajectory was done with the VMD 1.9.4a53 package (Humphrey et al., 1996).Molecular modeling figures were prepared with PyMOL.

Prediction of ADMET, physicochemical, and PAINS profiles
Lipophilicity (LogP ow ) and aqueous solubility (pS) were estimated by the ALogPS 3.0 neural network model implemented in the OCHEM platform (Sushko et al., 2011).Human intestinal absorption (HIA) (Radchenko et al., 2016), blood-brain barrier distribution/permeability (LogBB) (Dyabina et al., 2016;Radchenko et al., 2020), and hERGmediated cardiac toxicity risk (channel affinity pK i and inhibitory activity pIC 50 ) (Radchenko et al., 2017) were estimated using the integrated online service for the prediction of ADMET properties.This service implements predictive QSAR models based on accurate and representative training sets, fragmental descriptors, and artificial neural networks.The quantitative estimate of druglikeness (QED) values (Bickerton et al., 2012) were calculated, and the Pan Assay INterference compoundS (PAINS) alerts were checked using RDKit version 2021.09.2 software.

Results and discussion
3.1 Chemistry.Synthesis of 9-substituted acridines Currently, 9-substituted acridines can be obtained by several approaches.The classical method for the preparation of acridine derivatives is based on high-temperature condensation of diphenylamine and carboxylic acid in the presence of zinc chloride (Bernthsen, 1884) (Pathway A, Figure 2).Another method consists of preliminary functionalization of acridine and subsequent substitution of the introduced group by a nucleophile in the presence of transition-metal salts (Liu et al., 2013;Zhilyaev et al., 2022) (Pathway B, Figure 2).The presented strategies do not exclude a number of shortcomings.For example, the desire to introduce auxiliary groups, the use of catalysts and additional ligands, the employment of high temperature processes, and the need to separate reaction products from metal-containing byproducts complicate the preparation of target acridines.In addition, such accompanying negative factors as the high cost of the reaction process and, in some cases, low yields of the final products make the method inefficient and unprofitable.However, an alternative approach to functionalized acridines is nucleophilic aromatic substitution of hydrogen (S N H ) (Chupakhin et al., 1994;Charushin and Chupakhin, 2005;Makosza, 2010;Mąkosza, 2011;Mąkosza and Wojciechowski, 2014).This method makes it possible to obtain 9-substituted acridines efficiently and directly, avoiding the disadvantages mentioned above.
The S N H reactions proceed in two stages.The first one is nucleophilic addition to an aromatic substrate to form an intermediate (ϭ H -adduct).The ϭ H -adducts, e.g., in the case of acridine, are stable compounds, which makes it possible to comprehensively study their physicochemical properties and biological activities (Chupakhin et al., 2017;Volkov et al., 2018).The second stage is characterized by an oxidative process with formation of the target-functionalized acridine (Pathway C, Figure 2).We used the S N H approach described in detail in a recent publication (Shchepochkin et al., 2021) to obtain the 9-phosphoryl-9,10-dihydroacridines 1a-f and 9-phosphorylacridines 2a-f studied in this work (Figure 1).Briefly, acridine and the corresponding phosphonate were stirred without solvent under an argon atmosphere at 75 °C-80 °C for 2-7 h.9-Phosphoryl-9,10dihydroacridines 1a-f were isolated in 85%-95% yields.The corresponding aromatized compounds 2a-f were obtained in 81%-89% yields by electrochemical oxidation of 1a-f.
Figure 3 illustrates the structures of the previously described compounds, which were the subject of the research in the present work.

Inhibition studies of AChE, BChE and CES. Structure-activity relationships
Table 1 lists the components of the esterase profile of our compounds, i.e., their inhibitory potencies against the enzymes of cholinergic neurotransmission, AChE and BChE, and a structurally related off-target enzyme, CES (Makhaeva et al., 2016;Makhaeva et al., 2019b).
As can be seen from Table 1, all tested compounds weakly inhibited AChE, while a number of compounds demonstrated effective inhibition of BChE.
The most effective BChE inhibitors were found among the series of phosphorylated dihydroacridines.Moreover, the influence of the structure of the phosphorus-containing fragment on the inhibitory activity is clearly seen: dialkylphosphonates weakly inhibited BChE, but the introduction of aryl fragments increased the activity.Thus, diphenylphosphonate 1c was a moderate inhibitor (IC 50 = 48.0 ± 3.1 µM), while dibenzyloxy derivative 1d and its diphenethyl bioisostere 1e were effective inhibitors of BChE with IC 50 = 2.90 ± 0.23 µM and 3.22 ± 0.25 µM, respectively.The introduction of a chlorine atom into the para-position of the phenethyl fragment of 1e (compound 1f) reduced tenfold the anti-BChE activity (IC 50 = 21.7 ± 1.7 µM).
At the same time, aromatized analogs 2 of compounds 1 were largely inactive as BChE inhibitors.An exception was the acridine analog of the most effective dihydroacridine 1d-dibenzyloxy derivative 2d, which inhibited BChE with IC 50 = 6.90 ± 0.55 µM, i.e., it was only 2.4 times less effective than the corresponding dihydroacridine.
Weak inhibition of CES, an enzyme that catalyzes the hydrolysis of numerous ester-containing drugs, is a positive property of the studied compounds because this decreases the likelihood of unwanted drug-drug interactions in the event of their use in AD therapy (Tsurkan et al., 2013;Makhaeva et al., 2019b).

Kinetic studies of BChE inhibition
The most active BChE inhibitor 1d was selected for inhibition kinetics studies.Lineweaver-Burk plots-double reciprocal representations of Michaelis-Menten parameters-were used to assess the type of inhibition.Graphical analysis of the kinetic data on BChE inhibition by the tested compound (Figure 4) demonstrates changes in both K m and V max values; this result attests to a mixed type of inhibition.The values obtained for the competitive component (K i ) and the non-competitive component (αK i ) of the constants of BChE inhibition by compound 1d were 2.22 ± 0.19 µM and 11.5 ± 0.9 µM, respectively.

Molecular docking to AChE and BChE
To investigate the structural origins of the observed differences in inhibitory activity, we performed molecular docking to AChE and BChE for the most active dihydroacridine derivatives, namely, the bioisosteric compounds 1d and 1e and their aromatized analogs 2d and 2e.
According to the results of molecular docking, compounds with benzyloxy and phenethyl substituents 1d,e, and 2d,e were able to bind to the AChE active site gorge in a similar manner (Figure 5).However, in this case, the bulky dihydroacridine/acridine and benzyloxy/phenethyl groups were located below amino acid residues Tyr341 and Tyr124, which are the part of a narrow bottleneck (Sussman et al., 1991;Wlodek et al., 1997).This makes trafficking of the ligands to the bottom of the gorge kinetically hindered (Lushchekina and Masson, 2020), thus reducing their inhibitory efficacy.
With respect to BChE docking (Figure 6), a significant difference of binding to the enzyme active site at the bottom of the gorge was observed between dihydroacridine/acridine compounds 1d,e and 2d,e with benzyloxy/phenethyl substituents.Due to the wider active site gorge of BChE compared to AChE (Saxena et al., 1997), no kinetic difficulties of such binding were expected.
According to the docking results, the dihydroacridine derivatives 1d,e form direct hydrogen bonds with the Tyr332 and D70 side chains (Figure 6A).There is also a theoretical possibility of interaction of the phosphoryl group with the Thr120 side chain oxygen atom through a bridging water molecule (Figure 6A).According to X-ray crystallography (Koellner et al., 2000;Bourne et al., 2010;Berg et al., 2011), and molecular modeling (Nascimento et al., 2017;Makhaeva et al., 2021;van der Westhuizen et al., 2022), such interactions are typical for protein-ligand interactions in the active site gorge of cholinesterases.
Regarding acridines 2d and 2e, no specific interactions were observed, which agrees with their lower experimentally observed inhibitory activity.However, interactions of the acridine fragment of both compounds with the Trp82 main chain oxygen atom are

FIGURE 3
Structures of the studied acridine derivatives: 9-phosphoryl-9,10-dihydroacridines 1a-f and 9-phosphorylacridines 2a-f.Frontiers in Pharmacology frontiersin.org07 possible (Figure 6B).We observed such a water-mediated interaction for the similar amiridine fragment and the homologous AChE residue Trp86 in molecular dynamics simulations (Makhaeva et al., 2021).As observed with dihydroacridine derivatives, the phosphoryl group of the acridine compounds was located in such a way to suggest that a similar water molecule-bridged interaction occurred with the oxygen atom of the Thr120 side chain (Figure 6B).Regarding the dibenzyloxy group of compound 2d, such interactions are also possible for the oxygen atom (Figure 6B), which is consistent with its higher inhibitory activity compared to compound 2e (Table 1).

Molecular dynamics simulations of the complex of compound 1d with BChE
We performed MD simulations for the complex of the most active compound 1d with BChE.During the MD trajectory, the ligand remained bound to the enzyme, though it had reoriented, and the resulting binding pose (Figure 7) differed from the docked one (Figure 6A) in specific details.While molecular docking showed that the dihydroacridine group interacted with side chains of the PAS residues Asp70 and Tyr332, these interactions were disrupted shortly after the start of the MD simulation (Figure 8A).Instead, the inhibitor reoriented so that the dihydroacridine group established new interactions with the side chain of Trp82 after 15 ns of simulation (Figure 8B).This residue is located deeper in the gorge than Asp70 and Tyr332 and forms the active site as a part of the cation-binding compartment.The newly established π-cation stacking or T-stacking interactions of the dihydroacridine fragment were maintained during the remainder of the MD trajectory.In addition, T-stacking interactions of one of the ligand's phenyl rings with the Trp231 indole ring were observed during the entire MD trajectory (Figure 8C).The reorientation of the ligand in the active site gorge of BChE took place during the first 15 ns of the simulation and included temporary displacement of the phosphate group.After this, the phosphate group returned to the position outside the oxyanion hole and close to the Thr120 side chain (Figure 7; Figure 8D).The MD simulation confirmed that their interaction was maintained mainly through frequently exchanging bridging water molecules (Figure 9).However, occasional direct hydrogen bonding is also possible due to thermal motion (Figure 8D).

Inhibition of β-amyloid (1-42) (Aβ 42 ) selfaggregation
The in vitro inhibitory activity of the test compounds against Aβ 42 self-aggregation was determined using the thioflavin T (ThT) fluorimetric assay (LeVine, 1999;Bartolini et al., 2003;Munoz-Ruiz et al., 2005;Bartolini et al., 2011).This widely used procedure is based on specific binding of the fluorescent dye ThT to the β-sheets of assembled amyloid fibrils leading to a significant increase in fluorescence signal (Biancalana and Koide, 2010).Therefore, the decrease in ThT fluorescence in the presence of the studied compound correlates with its activity to inhibit the formation of amyloid aggregates.
As can be seen from Table 1, the ability of the studied compounds to inhibit the self-aggregation of Aβ 42 depends both on the structure of their acridine moiety and the substituents at the phosphorus atom; moreover, the structureactivity relationship largely coincides with that observed for BChE inhibition.
Indeed, acridine derivatives 2 inhibit the self-aggregation of Aβ 42 very weakly or do not inhibit at all.The ability of dihydroacridines 1 to block Aβ 42 self-aggregation depends on the structure of the phosphoryl fragment: dialkoxy derivatives are weak inhibitors, but the introduction of aryl substituents increases activity, which increases upon going from diphenoxy (1s) to dibenzyloxy (1d) substituents.Compound 1d exhibits the maximum inhibitory activity and suppresses the formation of amyloid aggregates by 58.9% ± 4.7%.Its bioisosteric analog, the diphenethyl derivative 1e, also has high activity, inhibiting Aβ 42 self-aggregation by 46.9% ± 4.2%.Adding a chlorine atom to the para-position of the phenethyl fragment 1e (compound 1f) slightly reduces the inhibitor activity.

Molecular docking to Aβ 42
Molecular docking did not reveal a direct explanation of the experimentally observed differences in the ability of acridine/ dihydroacridine compounds to inhibit Aβ 42 self-aggregation.There were slight differences in estimated binding energies (Supplementary Table S1) and number of contacts (Supplementary Table S2) of dihydroacridine derivatives 1d,e compared to acridine derivatives 2d,e with Aβ 42 conformers obtained from the NMR structure (PDB: 1IYT) (Crescenzi et al., 2002) [see details in (Makhaeva et al., 2022)].Although these differences could be considered minor, they are in line with different conformations of the Aβ 42 peptide used as molecular docking targets.Another plausible reason for the experimentally observed substantial differences between active dihydroacridine inhibitors and practically inactive acridine compounds could be related to the different ability of planar aromatic acridines to self-associate through π-π stacking interactions compared to non-planar dihydroacridines.Such self-stacking of acridine derivatives is well known (Evstigneev et al., 2006;Franco Pinto et al., 2022) and could compete with binding to the Aβ 42 peptide (Gao et al., 1991;Buurma and Haq, 2008).

Antioxidant activity (AOA)
Table 2 lists the results of our determinations of the AOA of compounds 1a-f and 2a-f using the ABTS and FRAP assays.In the ABTS test, the radical cation ABTS •+ reacts with an antioxidant via one or both of the following singleelectron transfer (SET) or hydrogen-atom transfer (HAT).In the FRAP test, the ferric 2,4,6-tripyridyl-s-triazine complex [Fe (TPTZ) 2 ] 3+ is reduced to the corresponding ferrous complex [Fe (TPTZ) 2 ] 2+ by the SET mechanism.In these tests, we used Trolox and ascorbic acid as the reference and positive control compounds, respectively.
All derivatives of 9,10-dihydroacridine 1 demonstrated high radical-scavenging activity in the ABTS test at levels near or slightly above that of Trolox, the standard antioxidant.In contrast, the 9-phosphoryl-acridines 2 were not active in the ABTS test.It should also be noted that compounds 1a-d exhibited a high initial rate of the ABTS •+ binding reaction, comparable to Trolox (the maximum degree of radical binding was achieved within 1 min).This fact is consistent with the SET mechanism for the antiradical activity of these compounds.A slight decrease in the radical-scavenging activity was observed for the phenethyl derivative 1e and its para-Cl-substituted analog 1f, which was also accompanied by a decrease in the reaction rate (the time to reach the maximum degree of radical binding increased from 1 to 30 min).
All dihydroacridine derivatives 1a-f also showed high ironreducing activity in the FRAP test, at the level or above that of Trolox.Moreover, these compounds were relatively rapid antioxidants, reaching the maximum effect within 4 min.The high activity of dihydroacridines 1a-f in the Fe 3+ -reducing test is probably directly related to the ease of their electrochemical oxidation to acridines (Shchepochkin et al., 2021).The dimethoxy derivative 1a (1.60 ± 0.01 TE) was the lead compound in this series, and the least active compound was para-Cl-substituted diphenethylphosphoryl dihydroacridine 1f (0.81 ± 0.02 TE).In general, the results of the ABTS and FRAP tests were in good agreement with each other.
Phosphoryl acridines 2a-f had almost no activity in the FRAP test.Only dimethoxy and diethoxy derivatives 2a,b, which are the aromatic analogs of the most active compounds 1a,b in the dihydroacridine series, showed detectable activity.
In both methods, reduction can occur by either the direct SET mechanism characterized by the ionization potential (IP), or by a hydrogen atom abstraction from the antioxidant molecule, when an electron is transferred to the radical and a proton to a solvent molecule.In the latter case, the actual antioxidant mechanism may be a complex multistage process, but the overall reaction can be characterized by the enthalpy of a hydrogen atom abstraction, i.e., the bond dissociation enthalpy, also known as the bond dissociation energy (BDE).
The quantum mechanical (QM) characteristics of possible antioxidant reactions for dihydroacridines and acridines were calculated taking two items into account: 1) the protonation state of the investigated structures in water and ethanol for the FRAP and ABTS tests, respectively; and 2) the method of synthesizing acridines from dihydroacridines by two-electron transfer electrochemical oxidation (Shchepochkin et al., 2021).The second item suggested a two-stage mechanism for the interaction of the antioxidant with ABTS •+ or FRAP molecules.
The calculated IP and BDE values for acridines were much higher than the corresponding values for dihydroacridines.Moreover, the characteristics of acridines were close to each other, as were the characteristics of dihydroacridines, which agrees with similar experimental results for compounds 2a and 1a, respectively.A detailed description of the approach that was used    A noticeably higher AOA of compound 1a with methoxy substituents compared to other compounds 1 in the FRAP test and the similar AOA in the entire series of compounds 1 in the ABTS test could be explained by the different access of antioxidant molecules to the ABTS •+ radical versus the [Fe (TPTZ) 2 ] 3+ cation.Indeed, [Fe (TPTZ) 2 ] 3+ , with a threedimensional propeller structure, is bulkier than the quasione-dimensional structure of ABTS •+ (Supplementary Figure S1), which hinders access for bulky antioxidants.

Prediction of ADMET, physicochemical, and PAINS profiles
Table 3 shows the predicted ADMET properties and physicochemical characteristics that we computed for compounds 1a-f and 2a-f.As can be seen, with the exception of the phenethyl and chlorophenethyl derivatives 1e-f and 2e-f, we obtained favorable values for intestinal absorption, indicating that the compounds would be expected to be bioavailable when administered orally.Note that it is possible that the unfavorable numbers for compounds 1e-f and 2e-f were likely due to their being outside of the applicability domain of the model.Given the high BBB permeability values, the compounds would be expected to enter the brain to exert effects on CNS targets; this is especially so for the benzyl and phenethyl derivatives.Parameters for cardiac toxicity risk, hERG pK i and pIC 50 , were within 5.0-7.9log units, near the center of the possible range of 3-9 log units.Lipophilicities, as assessed by computed LogP values, were in some cases outside of the classical Lipinsky rule of 5 range, but these values were deemed unreliable owing to their being outside of the applicability domain of the model.Otherwise, the molecular weights and predicted aqueous solubility values were near or within acceptable limits for drug-like molecules.Integral quantitative estimates of drug likeness (QED) fell within a range of 0.2-0.9; the most active compounds, 1d,e, scored 0.3 for this parameter.Finally, no alerts were identified by the Pan Assay INterference compoundS (PAINS) filter.
Taken together, the results of the computed ADMET, physicochemical, and PAINS profiles indicate that the lead compounds were acceptable for being advanced to further optimization and experimental studies of efficacy and safety.Frontiers in Pharmacology frontiersin.org13 Thus, studying the esterase profile of two new groups of acridine derivatives, 9-phosphoryl-9,10-dihydroacridines 1 and 9-phosphorylacridines 2, showed that all new compounds weakly inhibited AChE.Dihydroacridines with aryl substituents in the phosphoryl fragment inhibited BChE, with dibenzyloxy derivative 1d and its diphenethyl bioisostere 1e being the most active.Among acridines 2, only one compound 2d, an aromatized analog of 1d, proved to be an effective BChE inhibitor.Using 9-bis(benzyloxy)phosphoryl-9,10dihydroacridine 1d as an example, a mixed mechanism of BChE inhibition was demonstrated from a kinetics analysis.The results of molecular docking served to explain the experimentally determined parameters of the potency, selectivity, and mechanism of cholinesterases inhibition by the acridine derivatives.Weak inhibition of CES, an off-target esterase, is a positive characteristic of the studied compounds, because this reduces the likelihood of unwanted drug-drug interactions in the case of their use in AD therapy.
The ability of the studied acridine derivatives to inhibit the selfaggregation of Aβ 42 depended on both the structure of the acridine moiety and the structure of the substituents at the phosphorus atom.Moreover, the structure-activity relationship largely coincided with that observed for BChE inhibition.Dihydroacridines 1, especially with aryl substituents in the phosphoryl moiety, were able to block Aβ 42 self-aggregation.The most active were the dibenzyloxy derivative 1d and its bioisosteric analog, the diphenethyl derivative 1e.On the other hand, acridine derivatives 2 inhibited Aβ 42 self-aggregation weakly or not at all.Such a difference may be connected to the different ability to self-associate through π-π stacking interactions of the planar aromatic structure of acridines compared to non-planar dihydroacridines, which could compete with their binding to the Aβ 42 peptide.
Calculated ADMET parameters of the test compounds predicted favorable intestinal absorption, good blood-brain barrier permeability, and cardiac toxicity potential.
In summary, compounds 1d and 1e with dibenzyloxy-and diphenethyl-substituents were found to display high inhibition of BChE activity and Aβ 42 self-aggregation, high antioxidant capability, and favorable predicted ADMET properties.Therefore, these molecules can be considered lead compounds and are recommended for further in-depth studies as promising anti-AD agents.Frontiers in Pharmacology frontiersin.org14 Makhaeva et al. 10.3389/fphar.2023.1219980

FIGURE 2
FIGURE 2Methods for the preparation of 9-substituted acridines.

FIGURE 4
FIGURE 4 Double-reciprocal (Lineweaver-Burk) plots of the steady state inhibition of BChE by compound 1d.

FIGURE 5
FIGURE 5Binding modes of compounds 1d,e (carbon atoms colored green/magenta, respectively) and 2d,e (carbon atoms colored with lighter shades of the same colors) in the active site gorge of human AChE (PDB: 4EY7), according to molecular docking results.Yellow dashes show direct hydrogen bonding interactions.Orange dashes show the hypothetical possibility of water molecule-mediated interactions.

FIGURE 6
FIGURE 6Binding mode of compounds 1d,e (carbon atoms colored green or magenta, respectively) (A), and 2d,e (carbon atoms colored with lighter shades of the same colors) (B) in the active site gorge of human BChE (PDB: 1P0I), according to molecular docking results.Yellow dashes show direct hydrogen bonding interactions.Orange dashes show the hypothetical possibility of water molecule-mediated interactions.

FIGURE 7 A
FIGURE 7 A snapshot from the MD simulation of the complex of compound 1d with BChE, showing the main interactions in the complex after the ligand reorientation discussed in the text.Yellow dashed lines indicate hydrogen bonds, and orange dashes show stacking interactions.The ligand's atoms referred to in the following figure are labeled.Note the presence of a bridging water molecule whose hydrogen atoms form hydrogen bonds with the Tyr120 O γ atom and the ligand O2 atom.

FIGURE 9
FIGURE 9Bridging of the ligand phosphate group and Thr120 side chain by water molecules (LigO2•••H 1/2 -O-H 1/2 •• Thr120_O γ ) identifiedin the MD simulation of the complex between compound 1d with BChE.Each line shows the minimum of the two distances between each of the designated water molecule hydrogen atoms and enzyme or ligand oxygen atom.A water molecule was considered bridging when such H-O distances were less than 2 Å simultaneously for the ligand O2 and the enzyme Thr120_O γ atoms; pairs of these distances for the same water molecule are shown with different shades of the same color.Along the MD trajectory, 133 different water molecules participated in bridging defined in such a way.The plot shows distances for a few water molecules that were most frequently identified as bridging.For clarity, distances for the other type of bridging (LigO2•••H 1/2 -O•• Thr120_H γ ) are not shown.

FIGURE 10
FIGURE 10 Two-stage mechanism of the antioxidant action of dihydroacridines in the ABTS test using compound 1a as an example.The parent dihydroacridine 1a (AH C H N ) is circled in green, the final acridine 2a (A) is circled in red, and the protonated form of acridine (AH N + ) is circled in blue.The calculated QM characteristics of each stage are shown along the corresponding arrows indicating the reaction."Solv" is the solvent molecule.

TABLE 1
Esterase profiles of the compounds and their inhibition of Aβ 42 self-aggregation.

TABLE 1 (
Continued) Esterase profiles of the compounds and their inhibition of Aβ 42 self-aggregation.Values without units of measurement for BChE inhibition correspond to % inhibition at 20 µM.For active compounds, BChE inhibition is presented as IC 50 ± SEM μM, n = 3. d Tacrine IC 50 AChE = 0.601 ± 0.047 µM.Inhibition of Aβ 42 self-aggregation (50 µM) by the tested compound at 100 µM concentration.n. d.-not determined.n. a.-not active.Data are expressed as mean ± SEM, n = 3. IC 50 BChE values for the most active compounds are shown in boldface font.
c a

TABLE 2
Antioxidant activity (AOA) of compounds 1a-f and 2a-f in the ABTS and FRAP tests.

TABLE 2 (
Continued) Antioxidant activity (AOA) of compounds 1a-f and 2a-f in the ABTS and FRAP tests.
a TEAC, Trolox equivalent antioxidant capacity (ABTS) and TE-AOA, in Trolox equivalents (FRAP) (for the calculations, see Materials and methods).b Compound concentration required for a 50% reduction in the concentration of the ABTS radical cation.n.d.-not determined.n.a.-not active.